Background: Clinical outcomes after isolated infrapopliteal angioplasty for critical limb ischemia (CLI) in patients on hemodialysis (HD) are largely unknown. Methods: This study obtained the data from multi-center retrospective study: Japan BElow-the-knee Artery Treatment multi-center registry (J-BEAT registry). In 898 serial patients with 1068 who underwent end vascular therapy for CLI from 2004 to 2010, Subjects were 406 serial patients with 465 limbs who underwent balloon angioplasty for primary treatment of isolated infrapopliteal lesions. Subjects were classified into two groups for comparative study of clinical outcomes: the patients on HD: HD group (242 patients, 283 limbs) and not on HD: non-HD group (164 patients, 182 limbs). Results: The HD group had a higher percentage of patients with hypertension (83.1 vs. 68.9% P=0.001), coronary artery disease (60.3 vs. 39.0%, P<0.001), major tissue loss in treated limb (83.0 vs. 73.6%, P=0.014).But,there was no significant statistically difference in the ratio of diabetic patients (69.0 vs. 68.9%). In twelve-month clinical results, there was no statistically difference in the rate of major amputation (19.2 vs. 7.3%) between the two groups. However, the percentage of repeat angioplasty for the treated limb (32.8 vs. 17.5%, p=0.002) and all-caused death (29.5 vs. 14.6 %, p=0.003) in the HD group was significantly higher than that in non-HD group. The HD group had a significantly lower rate of freedom from major amputation or all-caused death in about 542±434 days follow-up compared to the non-HD group (logrank test p<0.001). In multivariate analysis of major amputation in patients on HD, C-reactive protein more than 3.0 IU/L (OR=3.32, 95%CI 1.76-6.71, P<0.001), diabetes mellitus (OR=2.58, 95%CI 1.12-4.61, P=0.024) or smoking (OR=2.32, 95%CI 1.16-4.59, P=0.017) were significant predictors . Conclusion: The limb salvage rate after infrapopliteal angioplasty for CLI in HD patients was acceptable at 12 month, but the prognosis was poor in long term outcomes.
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Midwest Cardiovascular Research Foundation, Davenport, IA; 2 Presbyterian Hospital, Dallas, TX; 3 West Chester Medical Center, Bronx, NY; 4 Methodist Hospital, Memphis, TN; 5 Emory University, Atlanta, GA; 6 Utah Cardiology, Layton, UT; 7 Metro Health Hospital, Wyoming, MI Background: CLI patients frequently present with severely calcified tibial stenoses, resulting in starvation of blood flow to the feet, continuation of limb pain at rest, and exacerbation of nonhealing wounds. Endovascular treatment with the Diamondback 360° Orbital PAD System (DB360) may have advantages in modifying calcified lesions to allow lower pressure adjunctive balloon, less need for bailout stenting and improved patient outcomes. This prospective, multi-center, randomized pilot study compares the acute, mid-and long-term outcomes of the DB360 versus plain old balloon angioplasty (POBA) in calcified infrapopliteal arteries. Methods: Fifty subjects were randomized to DB360 (25) or POBA (25). Primary endpoint was acute device success of ≤ 30% residual stenosis with no dissection type C-F. Symptomatic improvements, revascularization rates and economic data were recorded. Results: All patients had CLI and calcified infrapopliteal lesions; Rutherford 4 (rest pain) 50%, Rutherford 5 (minor tissue loss) 42%, and Rutherford 6 (major tissue loss) 8%. DB360 arm: 30 lesions; 88.5 mm average lesion length; 135 seconds average device run time; 6.18 atms average max balloon inflation. POBA arm: 35 lesions; 68.5 mm average lesion length; 12.8 atms average max balloon inflation for 112 seconds. Intraprocedural events included 1 (3.3%) dissection for DB360 versus 5 (14.3%) dissections for POBA, 1 (2.8%) perforation and 1 (2.8%) embolization for POBA. Bail-out stenting in 2 (6.7%) DB360 versus 4 (11.4%) POBA lesions. The primary endpoint was met in 93.3% of DB360 versus 76.5% of POBA lesions. Intraprocedural economic data showed cost equivalence between both arms. At six months, no deaths occurred in the DB360 arm versus 4 in the POBA arm. Two major amputations occurred in the DB360 arm versus 3 (1 major, 2 minor) and 1 revascularization in the POBA arm. In both arms, ABI improved (.75 to 0.98), and 82% were recategorized as Rutherford 0-3. Conclusion: CALCIUM 360 showed that DB360 outperforms POBA in calcified lesions by reducing major dissections and the need for stenting, both major limitations in treating CLI patients. Six-month results showed that DB360 did not increase procedural costs while reducing the ischemic burden of the limb.
TCT-571 Transvenous Intravascular Ultrasound-Guided Endovascular Treatment Of Chronic Total Occlusion Of A Lower Extremity Artery: A Novel Strategy
Yasuhiro Takahashi 1 , Ayaka Nozaki 1 , Hirotake Okazaki 1 , Masataka Kamiya 1 , Kyoichi Mizuno 2 1 The Fraternity Memorial Hospital, Tokyo, Japan; 2 Nippon Medical School, Tokyo, Japan Background: In recent years, endovascular treatment (EVT) of chronic total occlusion (CTO) of lower extremity arteries has made major advances with high success rates. Although treatments with duplex echo-guided recanalization, retrograde approaches, and subintimal angioplasty using a re-entry device have advanced, they have some disadvantages. Because of these limitations, safe and reliable methods are required for performing EVT of CTO of lower extremity arteries. Methods: We performed EVT using the transvenous intravascular ultrasound (IVUS)guided technique (TIG technique). This technique involves crossing the guidewire through the CTO lesion using images obtained by the IVUS catheter inserted in the vein parallel to the target artery ( Figure) . In this study, we investigated the primary success rate and complications of EVT using the TIG technique, which was performed in 19 patients with CTO of a lower extremity artery. Results: Primary success was achieved in all cases using the TIG technique. There were no complications such as guidewire perforation, arterial rupture after balloon dilation or stenting, or venous complications associated with this technique.
Conclusion:
The TIG technique resulted in a higher primary success and lesser complication rates, suggesting that this technique is safe and provides optimal results in EVT of CTO of lower extremity arteries. The TIG technique may be one of the most effective methods in EVT of lower extremity artery occlusive diseases. Background: A totally percutaneous approach to endovascular abdominal aortic aneurysm repair (PEVAR) has been shown in multiple single center reports to be feasible. Nonetheless, questions regarding the broader applicability of the approach remain due to the lack of a randomized multicenter trial. We report the methods and outcomes from the roll-in phase of the first prospective, multicenter trial of PEVAR. Methods: Among 19 institutions participating in the PEVAR Trial (NCT01070069), 38 consecutive patients with abdominal aortic aneurysm were enrolled in a roll-in phase www.JACC.TCTAbstracts2011
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JACC Vol 58/20/Suppl B | November 7-11, 2011 | TCT Abstracts/POSTER/Peripheral Vascular Intervention (non carotid, non neurovascular) between April 2010 and May 2011. PEVAR procedures with adjunctive 'pre-close' of the common femoral arteries (CFAs) targeted for large sheath access using the ProGlide or Prostar XL closure devices were performed using the Endologix IntuiTrak System. All patients were followed procedurally and to 30 days for major adverse events and access-related vascular complications. Results: Patients presented at a mean age of 71 years with mean aneurysm sac diameter of 5.6cm. Pre-close procedural success was 97% (37/38 patients). In one patient, ProGlide devices failed to achieve ipsilateral CFA hemostasis, leading to bleeding requiring transfusion and surgical vascular repair. All endovascular repairs were successful. No mortality or major adverse events occurred. Other pre-close related complications occurring within 30 days included pseudoaneurysm, lower extremity ischemia, and blood transfusion. Conclusion: PEVAR with adjunctive 'pre-close' techniques using the ProGlide or Prostar XL devices is safe and feasible as applied in this multicenter experience. Continued evaluation in a prospective, randomized trial is warranted.
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Long-term Mortality After Aortic Dissection in the Community -Results from the Kaiser Permanente Registry of Aortic Dissections (KP-RAD)
Cuong Lam 1 , Jackie Schwartz 1 , Kevin Izquierdo 1 , Aman Saw 1 , Vicken Aharonian 1 , Kevin Patel 1 , Raymond Chen 1 , George Vatakencherry 1 , Michael Jorgensen 1 , Kwok Yun 1 , William Gray 3, 1 , Somjot S Brar 1, 2 1 Regional Cardiac Cath Lab, Kaiser Permanente, Los Angeles, CA; 2 Kaiser Permanente, Pasadena, CA; 3 Columbia University, New York, NY Background: Survival estimates of patients with aortic dissection commonly come from tertiary care centers; such estimates may be biased by referral and selection bias. The survival rate of unselected patients with aortic dissection in the community remains poorly defined. Methods: Aortic dissection cases where identified from the Kaiser Permanente-Registry of Aortic Dissections (KP-RAD). This population-based registry was designed to capture consecutive cases of aortic dissections occurring among the approximately 3,000,000 health plan members in Southern California. Aortic dissections were categorized as either type A or B. The endpoint for the analysis was all-cause mortality. The failure rate by dissection type was compared using the Kaplan-Meier method. Results: There were 347 aortic dissection cases identified. Of these, 141 were type A aortic dissection and 206 were type B aortic dissection. The mean age of the cohort was 64 ± 16 years and 36% were female. The 30-day mortality for type A dissections was 10.0% and 4.4% for type B dissections. However, at 6 months, the event rates were similar; the mortality in the type A dissection group was 12.3% compared to 11.7% in the type B dissection group. The mortality rate by dissection type is shown in the figure.
Conclusion: Type A aortic dissections are associated with higher 30-day mortality compared to type B dissections. However, by 6-months the mortality rate is similar in both groups. Very close follow-up in the first six months after aortic dissection seems warranted.
TCT-574 Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy after Femoropopliteal Revascularization: A First in Man Study
Christopher D Owens 1, 2 , Warren J Gasper 1, 2 , Ji Min Kim 1 , Joseph Rapp 1, 2 , Marlene Grenon 1, 2 , Kirk Seward 3 1 University of California, San Francisco, San Francisco, CA; 2 San Francisco Veterans Administration Medical Center, San Francisco, CA; 3 Mercator MedSystems, Inc., San Leandro, CA Background: Endovascular treatment of the superficial femoral artery (SFA) is associated with an inflammatory response correlated with restenosis. Dexamethasone delivered into the vessel adventitia at the treatment site may abate post-intervention inflammation and reduce restenosis rates. Methods: Patients with TASC II A, B, and C disease of the SFA were eligible for this study. Following successful intervention, an adventitial micro-infusion catheter, (Bullfrog®, Mercator MedSystems, San Leandro, Calif.), was advanced over a 0.014" wire to the treated segment. Its micro-needle (0.9 mm long x 140 μm diameter) was deployed into the adventitia to deliver dexamethasone (DEX, 4 mg/ml) mixed with iodixanol contrast agent (80:20 ratio), providing fluoroscopic visualization. In total, 5 mg of DEX was infused per 5 cm of treated artery. Results: Six patients have been enrolled in this study (mean age, 66 years). Mean lesion length was 88 mm and included 3 TASC II As, 2 Bs, and 1 C lesion (4/6 were chronic total occlusions). Each case resulted in complete cylindrical distribution of DEX in the adventitia around the target artery with 100% technical success and no adverse events, Table 1 . Treatment required an average of 2.7 injections per patient.
Conclusion:
Adventitial drug delivery is a feasible alternative to luminal or intimal delivery modes. The micro-infusion catheter is a safe and efficient method to achieve adventitial drug delivery. Further study is warranted to determine if DEX treatment of the SFA decreases restenosis rates.
TCT-575 Thoracic Endovascular Aortic Repair for Acute Type A Dissection: A Computational and Anatomic Analysis of Technical Limitations for Available Devices
Sam Chitsaz 1, 2 , Nicolas Jaussaud 1, 2 , Alison Meadows 3 , Max Wintermark 1 , Neil Cambronero 1 , Ali N Azadani 1, 2 , David A Saloner 3, 2 , Timothy A Chuter 1 , Liang Ge 1, 2 , Elaine E Tseng 1, 2 1 Department of Surgery, University of California at San Francisco, San Francisco, CA; 2 San Francisco VA Medical Center, San Francisco, CA; 3 Department of Radiology, University of California at San Francisco, San Francisco, CA Background: Acute type A aortic dissection still carries a 25% mortality based on international registries, while mortality for complicated type B dissection has been significantly reduced with the advent of thoracic endovascular aortic repair (TEVAR). The purpose of this study was to simulate type A dissection by computational fluid dynamics (CFD) to determine the relationship of tearing force to dissection propagation, and to determine anatomic feasibility of TEVAR in patients with acute type A dissection by characterizing primary intimal tears using 64-multislice computerized tomography (MSCT). Methods: Computational models of aortic dissection were constructed. Dissection propagation was represented in single-and double-entry tear models. Impact of pressure field distribution on tearing force was determined. On the clinical side, radiology database was screened for acute type A aortic dissection on 64-slice CT scans. Seventeen patients were reviewed for physical characteristics of intimal tears. Potential obstacles for TEVAR were sought. Results: On CFD, tearing force for dissections with a single entry tear was approximately proportional to the rate of pressure rise and the second power of dissection length. Introduction of a second tear distally along the dissection away from the primary entry tear significantly reduced tearing force. On MSCT, ascending aorta (29%) and sinotubular junction (29%) were the most frequent regions where intimal tears originated. Location of intimal tears in nearly 75% of patients was inappropriate for TEVAR, and 94% of patients did not have sufficient proximal or distal landing zone required for secure fixation. Only one patient met all technical criteria for TEVAR using currently available devices. Conclusion: TEVAR for aortic dissection should ideally cover both entry and re-entry tears to reduce risk of propagation. Location of intimal tear, aortic valve insufficiency, and aortic diameter were major factors limiting use of TEVAR for acute type A dissection. Available stents used to treat type B dissection do not address anatomic constraints present in type A dissection in the majority of cases, such that new device development would be required.
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Use of Orbital Treatment in a High Volume Clinical Practice Modifies Non-Compliant Plaque to Deliver Durable Long-Term Results
Prakash Makam, Ricardo Guedes Cardiovascular Research of Northwest Indiana, LLC, Muenster, IN
Background: Resistant fibrotic and calcified plaques are a major limitation in the treatment of peripheral arterial disease (PAD). Balloon angioplasty typically ranges 8-16 atms in these plaques, and subsequent dissection rates range 40-74%, with bail-out stent rates as high as 40%. Plaque modification as a first-line endovascular therapy alters lesion compliance to prevent dissections and the need for stent placement. We report a single center experience utilizing the next generation orbital technology, called Predator 360 (Cardiovascular Systems, St. Paul, MN) to evaluate the long-term
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